Document is current
Any future updates will be listed below
-
Authors
Leyns, Cheryl E. G.
Holtzman, David M.
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (NS090934)
National Institute on Aging (AG04867801, AG053976)
Tau Consoritum
JPB Foundation
- License Information
-
More Information
Article History
Received: 10 April 2017
Accepted: 20 June 2017
First Online: 29 June 2017
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: CEGL and DMH are listed as inventors on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. DMH co-founded and is on the scientific advisory board of C2N Diagnostics, LLC. C2N Diagnostics, LLC has licensed certain anti-tau antibodies to AbbVie for therapeutic development. DMH is on the scientific advisory board of Proclara and consults for Genentech, Eli Lilly, Denali, AbbVie, and GlaxoSmithKline. The authors have no additional financial interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
